BTK Inhibitors as Sensitizing Agents in Solid Tumors

BTK Inhibitors as Sensitizing Agents in Solid Tumors provides a thorough review of mechanisms of multi-drug resistance in cancers, describing, in detail, the mechanisms, current studies and future directions of the role of BTK inhibitors in overcoming therapy resistance in cancer, including resistance to chemotherapy, targeted therapies and immunotherapy. The book discusses topics such as mechanisms of therapy resistance in cancer cells, BTK inhibitors in paclitaxel, docetaxel, platinum, BRAF and radio resistance. In addition, the book discusses ibrutinib and its role in immunotherapy resistance, novel BTK inhibitors and future perspectives.

This book is a valuable resource for cancer researchers, oncologists, graduate students, and members of the biomedical field who are interested in the potential of BTK inhibitors as sensitizing agent to resistant cancers.

• Provides a unique compilation of cutting-edge research on the emerging role of BTK inhibitors as chemosensitizers
• Focuses on pre-clinical and clinical studies, addressing efficacy of BTK inhibitors in the treatment of multi-drug resistant cancers
• Presents data, perspectives and thoughts from leading researchers who compile their knowledge on the topic based on their research work and clinical expertise